Is Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Tonix Pharmaceuticals Holding Corp. at current levels.
First non-opioid fibromyalgia drug in 20+ years is now on pharmacy shelves, and the market still trades it like a lottery ticket.
Where TNXP is headed
Tonix spent fifteen years and roughly a billion dollars getting a repurposed muscle relaxant across the FDA finish line for fibromyalgia. TONMYA (sublingual cyclobenzaprine) is now the first branded therapy approved for the condition since Savella in 2009, targeting a US patient pool north of 6 million people, most of whom cycle through pregabalin, duloxetine, and off-label opioids without much joy. By late 2027, if the launch tracks even modestly, Tonix should be running at $200-350M in TONMYA revenue with gross margins in the mid-80s. That alone would justify a market cap several multiples of today's $225M.
Read the full Compass Direction on TNXP
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $7.28).
See the full TNXP analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Tonix Pharmaceuticals Holding Corp. at current levels. First non-opioid fibromyalgia drug in 20+ years is now on pharmacy shelves, and the market still trades it like a lottery ticket.
What is TNXP's Compass Score?
Tonix Pharmaceuticals Holding Corp. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for TNXP?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the TNXP page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.